Your session is about to expire
← Back to Search
Behavioural Intervention
Virtual Reality Obstacle Detection for Visual Field Loss
N/A
Recruiting
Led By Jae-Hyun Jung, PhD
Research Sponsored by Massachusetts Eye and Ear Infirmary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Able to independently move short distances
Visual field loss, either peripheral field loss (<30 degrees diameter) or hemianopic field loss (blind in half of visual field)
Must not have
Any self-reported history of seizures (any type) in the last 6 months
Patients with any self-reported physical or mental disabilities, including cognitive dysfunction, balance problems, or other deficits that could impair their ability to respond to the stimuli presented in this study
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of four months
Awards & highlights
No Placebo-Only Group
Summary
This trial uses a VR headset to help people with visual field loss practice detecting and avoiding virtual pedestrians. The headset shows 3D images of people walking towards the user while they walk in a real-world setting. This helps improve their ability to avoid collisions in a safe environment.
Who is the study for?
This trial is for people with visual field loss, such as hemianopia or tunnel vision. Participants must have binocular vision within normal limits, at least partial peripheral vision, and a visual acuity of no worse than 20/100 in the weaker eye. They should be over 14 years old, healthy enough for sessions up to 3 hours, understand English, consent voluntarily, and move independently.
What is being tested?
The study is testing a new virtual reality (VR) system designed to help individuals with visual field loss detect obstacles while walking. It involves wearing a VR headset that simulates real-world environments and oncoming pedestrians in three dimensions.
What are the potential side effects?
While not explicitly stated, potential side effects may include discomfort from wearing the VR headset, motion sickness due to virtual reality exposure, eye strain from prolonged use of the device or temporary disorientation after using the VR system.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I can walk by myself for short distances.
Select...
I have lost vision in either half or the outer parts of my field of vision.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have had a seizure in the past 6 months.
Select...
I do not have any physical or mental disabilities that would affect my participation.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of four months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of four months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Response time
Secondary study objectives
Error rate
Head movement range
Pedestrian detection rate
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Field expansion viewExperimental Treatment1 Intervention
Various configurations of field expansion views will be additionally displayed on HMD
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Homonymous Hemianopia include visual field expansion techniques, such as the use of prisms and virtual reality (VR) head-mounted displays. Prisms work by shifting images from the non-seeing side to the seeing side, thereby expanding the visual field.
VR head-mounted displays create a simulated 3D environment that helps patients practice and improve their visual-motor coordination and hazard detection in a controlled setting. These mechanisms are crucial for Homonymous Hemianopia patients as they enhance their ability to navigate their environment safely and independently, improving their overall quality of life.
Effect of movement and vision on visual-motor adjustment to optical rearrangement.Wayfinding and Glaucoma: A Virtual Reality Experiment.Disparity vergence responses before versus after repetitive vergence therapy in binocularly normal controls.
Effect of movement and vision on visual-motor adjustment to optical rearrangement.Wayfinding and Glaucoma: A Virtual Reality Experiment.Disparity vergence responses before versus after repetitive vergence therapy in binocularly normal controls.
Find a Location
Who is running the clinical trial?
Massachusetts Eye and Ear InfirmaryLead Sponsor
108 Previous Clinical Trials
13,019 Total Patients Enrolled
National Eye Institute (NEI)NIH
554 Previous Clinical Trials
1,407,324 Total Patients Enrolled
1 Trials studying Quadrantanopia
280 Patients Enrolled for Quadrantanopia
Jae-Hyun Jung, PhDPrincipal InvestigatorAssistant Scientist
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I can walk by myself for short distances.I can complete activities lasting 2-3 hours without significant difficulty.I have lost vision in either half or the outer parts of my field of vision.I am 14 years old or older.I have had a seizure in the past 6 months.I do not have any physical or mental disabilities that would affect my participation.It seems like the criterion you provided is incomplete. Could you please provide more details or context so that I can assist you accurately?
Research Study Groups:
This trial has the following groups:- Group 1: Field expansion view
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Quadrantanopia Patient Testimony for trial: Trial Name: NCT05141604 — N/A
Share this study with friends
Copy Link
Messenger